TERT mutation	Solid Tumor	TERT mutation	Solid Tumor	Immunotherapy Sensitive: C2 – Inclusion Criteria Immunotherapy Sensitive : C2	Immunotherapy Sensitive: C2 – Inclusion Criteria Immunotherapy Sensitive : C2
TERT mutation	Hepatocellular Cancer	TERT mutation	Hepatocellular Cancer	bevacizumab + atezolizumab Resistant: C3 – Early Trials bevacizumab + atezolizumab Resistant : C3	bevacizumab + atezolizumab Resistant: C3 – Early Trials bevacizumab + atezolizumab Resistant : C3
TERT mutation	Squamous Cell Carcinoma of Head and Neck	TERT mutation	Squamous Cell Carcinoma of Head and Neck	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
TERT mutation	Soft Tissue Sarcoma	TERT mutation	Soft Tissue Sarcoma	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3
TERT mutation	Solid Tumor	TERT mutation	Solid Tumor	AST-487 Sensitive: D – Preclinical AST-487 Sensitive : D	AST-487 Sensitive: D – Preclinical AST-487 Sensitive : D

TERT mutation

Associations